Tiplasinin

Drug Profile

Tiplasinin

Alternative Names: PAI 039; Tiplaxtinin

Latest Information Update: 06 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Class Antithrombotics; Indoles; Small molecules
  • Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Thrombosis

Most Recent Events

  • 06 Aug 2009 Discontinued - Phase-I for Thrombosis in USA (PO)
  • 06 Aug 2009 Discontinued - Preclinical for Atherosclerosis in USA (PO)
  • 11 Oct 2005 A preclinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top